Natco Pharma Board Approves Adcock Ingram Stake Increase

Natco Pharma's Board of Directors has approved an investment of up to ₹1400 Crores in its wholly-owned subsidiary, Natco Pharma South Africa. Additionally, the board approved acquiring 19,618,825 shares of Adcock Ingram Holdings Proprietary Limited for ₹1069 Crores, increasing Natco's stake from 35.75% to 49%. Adcock Ingram reported a topline of US$423 million and EBITDA of ~US$59 million for the nine months ending March 31, 2026. Post-acquisition, Natco will recognize 49% of Adcock Ingram's profit after tax. The meeting also considered other business items.